Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of RSVpreF vaccine in healthy adults
NCT03529773Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Apr 2018; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03529773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529773.